Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma (vol 12, pg 1421, 2017)

被引：0
|
作者：
Kao, S. C.
Cheng, Y. Y.
Williams, M.
机构：
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：587 / 587
页数：1
相关论文
共 50 条
  • [31] PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study
    Jin, Liu
    Gu, Weiling
    Li, Xueqin
    Xie, Liang
    Wang, Linhong
    Chen, Zhongwen
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [32] Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy
    White, Michael G.
    Schulte, Jefree J.
    Xue, Lai
    Berger, Yaniv
    Schuitevoerder, Darryl
    Vining, Charles C.
    Kindler, Hedy L.
    Husain, Aliya
    Turaga, Kiran K.
    Eng, Oliver S.
    BRITISH JOURNAL OF CANCER, 2021, 124 (03) : 564 - 566
  • [33] PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review
    Zhou, Maggie
    Joshi, Nitin
    Raj, Kavitha P.
    Wakelee, Heather
    Neal, Joel W.
    CLINICAL LUNG CANCER, 2021, 22 (03) : E329 - E335
  • [34] Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy
    Michael G. White
    Jefree J. Schulte
    Lai Xue
    Yaniv Berger
    Darryl Schuitevoerder
    Charles C. Vining
    Hedy L. Kindler
    Aliya Husain
    Kiran K. Turaga
    Oliver S. Eng
    British Journal of Cancer, 2021, 124 : 564 - 566
  • [35] PD-L1 Reactivity of Tumor Cells Can Successfully Be Determined in Malignant Mesothelioma Effusions
    Mansour, M.
    Seidal, T.
    Mager, U.
    Baigi, A.
    Dobra, K.
    Dejmek, A.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2020 - S2020
  • [36] The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells
    Lu, Chunwan
    Redd, Priscilla S.
    Lee, Jeffrey R.
    Savage, Natasha
    Liu, Kebin
    ONCOIMMUNOLOGY, 2016, 5 (12):
  • [37] Comment on “Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy”
    Haitang Yang
    Sean R. R. Hall
    Beibei Sun
    Feng Yao
    British Journal of Cancer, 2021, 124 : 1177 - 1178
  • [38] Comment on "Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy"
    Yang, Haitang
    Hall, Sean R. R.
    Sun, Beibei
    Yao, Feng
    BRITISH JOURNAL OF CANCER, 2021, 124 (06) : 1177 - 1178
  • [39] A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
    Lee, Hyun-Sung
    Jang, Hee-Jin
    Ramineni, Maheshwari
    Wang, Daniel Y.
    Ramos, Daniela
    Choi, Jong Min
    Splawn, Taylor
    Espinoza, Monica
    Almarez, Michelle
    Hosey, Leandria
    Jo, Eunji
    Hilsenbeck, Susan
    Amos, Christopher I.
    Ripley, R. Taylor
    Burt, Bryan M.
    CLINICAL CANCER RESEARCH, 2023, 29 (03) : 548 - 559
  • [40] Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression (vol 19, pg 1189, 2017)
    Garcia-Diaz, Angel
    Shin, Daniel Sanghoon
    Moreno, Blanca Homet
    Saco, Justin
    Escuin-Ordinas, Helena
    Rodriguez, Gabriel Abril
    Zaretsky, Jesse M.
    Sun, Lu
    Hugo, Willy
    Wang, Xiaoyan
    Parisi, Giulia
    Saus, Cristina Puig
    Torrejon, Davis Y.
    Graeber, Thomas G.
    Comin-Anduix, Begonya
    Hu-Lieskovan, Siwen
    Damoiseaux, Robert
    Lo, Roger S.
    Ribas, Antoni
    CELL REPORTS, 2019, 29 (11): : 3766 - 3766
12345